Emerald Bioventures Discloses 30.2% Stake in Galera Therapeutics Following Mandatory Preferred Stock Conversion
GRTX has more than doubled off its 52-week low of $0.015.
Summary
Emerald Bioventures, LLC now beneficially owns 30.2% of Galera Therapeutics' common stock after a mandatory conversion of Series B Preferred Stock on May 15, 2026.
Key Events · Ownership and Investor Activity · GRTX
-
Major Shareholder Update
Emerald Bioventures, LLC and Timothy Opler now beneficially own 61,029,978 shares of common stock in Galera Therapeutics.
-
Significant Ownership Stake
This represents approximately 30.2% of Galera Therapeutics' outstanding common stock.
-
Mandatory Preferred Stock Conversion
The increased stake resulted from the mandatory conversion of Series B Non-Voting Convertible Preferred Stock on May 15, 2026.
-
Influence on Corporate Events
This substantial ownership position is highly relevant given the company's ongoing merger with Obsidian Therapeutics and proposed reverse stock split.
Analysis · GRTX · Life Sciences
This Schedule 13D/A updates Emerald Bioventures' beneficial ownership in Galera Therapeutics, revealing a significant 30.2% stake following the mandatory conversion of preferred stock. This substantial ownership position gives Emerald Bioventures considerable influence over the company's strategic direction, particularly as Galera Therapeutics navigates a proposed reverse stock split and a definitive merger agreement with Obsidian Therapeutics.
At the time of this filing, GRTX was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $16.1M. The 52-week trading range was $0.02 to $0.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.